Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

NCT07718243 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin Cancer)
Non Small Cell Lung Cancer
Solid Tumor in Advanced Stage

Interventions

DRUG: Bexmarilimab 1mg/kg and nivolumab 1mg/kg
DRUG: Bexmarilimab 3mg/kg and nivolumab 1mg/kg
DRUG: Recommended Phase II Dose

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]
[object Object]
[object Object]